2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.
Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.
There has been a large, national increase in the number of patients going onto active surveillance programs, Chapin explains. Compared with the smaller proportion seen previously, researchers now are seeing that up to 40% of men who are diagnosed with low-risk tumors are going onto an active surveillance program.
Additionally, he says, the community is recognizing that not all prostate cancers are the same. Some prostate cancers are indolent and are unlikely to cause significant problems. Patients are becoming more aware of that; therefore, they are seeking out other options and not just choosing to go with active treatment.